Product Images Venlafaxine Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Venlafaxine Hydrochloride NDC 65862-527 by Aurobindo Pharma Limited, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a drug interaction report that includes recommendations for PK fold change and 90% CI for the drug cimetane interacting with the analyte "aniatxine", "veniatxine" and "venistaxing". It suggests caution and monitoring for blood pressure in patients with hypertension, patients who are elderly or have hepatic dysfunction. The clinical significance of this drug interaction is unknown. Dose adjustment is not recommended.*
This text appears to be a combination of random letters and numbers and is not readable. Therefore, it is not possible to generate a useful description.*
This is a prescription medication for Venlafaxine Hydrochloride, an extended-release capsule USP, with each capsule containing 75 mg of Venlafane hydrochloride USP. The usual dosage information is provided within the package, which contains 15 capsules. The medicine should be stored between 20°C and 25°C, and each capsule is provided separately for a different patient. The medication is distributed by Aurabindo Pharma USA, Inc., located in New Jersey, and made in India. The alphanumeric code TS/DRUGS/19/1093 is included on the package.*
This is a description of a medication called Venlafaxine Hydrochloride, which is an extended-release capsule containing 150 mg per capsule. The medication guide should be provided separately to each patient. There is also dosage information provided. The capsules should be stored at a temperature between 20°C - 25°C. It is distributed in the US by Aurabindo Pharma USA, Inc. The code TS/DRUGS/19/1093 is present with some additional information regarding printing.*
This is a description of Venlafaxine Hydrochloride Extended-Release Capsules USP medication. The text contains some distorted and incomplete characters, indicating that it was obtained by . The medication is intended for pharmaceutical use and comes in capsule form. The text also mentions a disposo modification and provides sopraay to each patient. Overall, due to the incomplete and incoherent characters, the description is not very useful and may not provide sufficient information.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.